Effect of Chondroitin Sulphate on Pro-Inflammatory Mediators and Disease Activity in Patients with Inflammatory Bowel Disease
| Autor: | Iván Guerra, Dolores Ochoa, F. Abad Santos, Fernando Bermejo, I. Moreno Arza, Javier P. Gisbert, María Chaparro, Alicia Algaba, Manuel Román, Pablo M. Linares |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Time Factors Angiogenesis Osteoarthritis Severity of Illness Index Inflammatory bowel disease Recurrence Severity of illness medicine Humans Prospective Studies Prospective cohort study Aged Pain Measurement Crohn's disease business.industry Chondroitin Sulfates Gastroenterology Interleukin Middle Aged Inflammatory Bowel Diseases medicine.disease Arthralgia Ulcerative colitis digestive system diseases Immunology Intercellular Signaling Peptides and Proteins Female Inflammation Mediators business Follow-Up Studies |
| Zdroj: | Digestion. 92:203-210 |
| ISSN: | 1421-9867 0012-2823 |
| Popis: | Background/Aims: To evaluate the incidence rate of relapse in patients with inflammatory bowel disease (IBD) undergoing chondroitin sulphate (CS) treatment and its effect on the concentrations of several pro-inflammatory proteins. Methods: Prospective, observational, 12-month follow-up study in patients with IBD in remission, starting CS (Condrosan®, Bioiberica S.A.) treatment for osteoarthritis (OA). Crohn's Disease Activity Index and modified Truelove-Witts severity index were calculated for Crohn's disease and ulcerative colitis (UC) respectively. Levels of vascular endothelial growth factor (VEGFA), -C, fibroblast growth factor 2, hepatocyte growth factor, angiopoietin (Ang)-1, Ang-2, transforming growth factor beta, tumour necrosis factor alpha, interleukin (IL)-1β, IL-6, IL-12, IL-17, IL-23, intracellular adhesion molecule-1, vascular adhesion molecule-1, matrix metalloproteinase-3 and PGE2 were quantified by ELISA. OA joint pain was evaluated using a visual analogue scale. Results: A total of 37 patients (19 UC and 18 Crohn's disease) were included. The mean values for OA joint pain decreased after 12 months from 5.9 ± 2.8 to 3.0 ± 2.3 (p < 0.05). Only 1 patient (with UC) flared during follow-up. The incidence rate of relapse was 3.4% per patient-year of follow-up. Mean serum VEGFA levels increased between baseline (492 pg/ml) and 12-month treatment (799 pg/ml; p < 0.05). Conclusion: The incidence of IBD relapse in patients under CS treatment was lower than that generally reported. This treatment might modulate VEGFA. CS decreases OA-related pain in patients with IBD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|